The Phase III trials will compare apricitabine (ATC) to the current standard of care in HIV–infected patients who are resistant to current drugs. The program is being conducted in North and South America, Europe, Africa, and Asia (including Australia).
Avexa also reported that all patients in the Phase IIb study have completed the 48 week dosing period and the final results are due in the first quarter of 2008.
Julian Chick, CEO of Avexa, said: “The high level of demand from clinics and physicians around the world to participate in the Phase III program indicates that physicians and patients believe ATC holds great importance for the improved treatment of drug-resistant HIV patients.”